Počet záznamů: 1  

Detection and quantitation of glutamate carboxypeptidase II in human blood

  1. 1.
    0428605 - ÚOCHB 2015 RIV US eng J - Článek v odborném periodiku
    Knedlík, Tomáš - Navrátil, Václav - Vik, V. - Pacík, D. - Šácha, Pavel - Konvalinka, Jan
    Detection and quantitation of glutamate carboxypeptidase II in human blood.
    Prostate. Roč. 74, č. 7 (2014), s. 768-780. ISSN 0270-4137. E-ISSN 1097-0045
    Grant CEP: GA ČR GAP304/12/0847
    Grant ostatní: OPPC(CZ) CZ.2.16/3.1.00/24016
    Institucionální podpora: RVO:61388963
    Klíčová slova: serum marker * glutamate carboxypeptidase II * plasma glutamate carboxypeptidase * prostate cancer * prostate-specific membrane antigen
    Kód oboru RIV: CE - Biochemie
    Impakt faktor: 3.565, rok: 2014

    Glutamate carboxypeptidase II (GCPII) is a transmembrane enzyme that cleaves N-acetyl-L-aspartyl-L-glutamate (NAAG) in the brain. GCPII is highly expressed in the prostate and prostate cancer and might be associated with prostate cancer progression. Another exopeptidase, plasma glutamate carboxypeptidase (PGCP), was reported to be similar to GCPII and to share its NAAG-hydrolyzing activity. We performed a radioenzymatic assay with [H-3]NAAG as a substrate to detect and quantify the enzymatic activity of GCPII in plasma. Using a specific antibody raised against native GCPII (2G7), we immunoprecipitated GCPII from human plasma. We also cloned two PGCP constructs, expressed them in insect cells, and tested them for their NAAG-hydrolyzing activity. We detected GCPII protein in human plasma and found that its concentration ranges between 1.3 and 17.2 ng/ml in volunteers not diagnosed with prostate cancer. Recombinant PGCP was enzymatically active but exhibited no NAAG-hydrolyzing activity. GCPII is present in human blood, and its concentration within a healthy population varies. Recombinant PGCP does not hydrolyze NAAG, suggesting that GCPII alone is responsible for the NAAG-hydrolyzing activity observed in human blood. The potential correlation between GCPII serum levels and the disease status of prostate cancer patients will be further investigated.
    Trvalý link: http://hdl.handle.net/11104/0233924

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.